---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-022974"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:30:08.933432+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IMDX Q2 rev $518K, net loss $9.7M; FDA on track for GraftAssureDx submission by year-end

## Summary
- Revenue $518K vs $104K YoY; gross margin 67.6%, up from 62% in Q1.
- Net loss $9.7M ($0.30/sh); non-GAAP operating loss $5.98M.
- Cash $26.0M; quarterly cash spend ~$6M, in line with target.
- FDA submission for GraftAssureDx on track for end-2025; marketing authorization expected mid-2026.
- First RUO kit sale to Swiss hospital; Medicare boost to $2,753/test.

## SEC filing metadata
- accession: 0001641172-25-022974
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000164117225022974/0001641172-25-022974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000164117225022974/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-022974
- JSON: https://secwatch.observer/filing/0001641172-25-022974.json
- Plain text: https://secwatch.observer/filing/0001641172-25-022974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.